Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities researchers at Oppenheimer Holdings issued their FY2020 earnings per share (EPS) estimates for Neurocrine Biosciences in a report issued on Tuesday. Oppenheimer Holdings analyst J. Olson forecasts that the firm will post earnings per share of $1.92 for the year. Oppenheimer Holdings currently has a “Buy” rating and a $60.00 price target on the stock.

NBIX has been the topic of a number of other research reports. Piper Jaffray Companies reiterated an “overweight” rating and set a $96.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, December 7th. Cowen and Company set a $65.00 target price on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a report on Wednesday, January 18th. BMO Capital Markets restated an “outperform” rating and set a $72.00 target price (up from $66.00) on shares of Neurocrine Biosciences in a report on Thursday, October 27th. Robert W. Baird restated a “buy” rating and set a $66.00 target price on shares of Neurocrine Biosciences in a report on Sunday, January 8th. Finally, Needham & Company LLC restated a “buy” rating and set a $62.00 target price on shares of Neurocrine Biosciences in a report on Thursday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and fourteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $67.23.

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

This report was reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was illegally copied and republished in violation of US and international trademark and copyright law. The original version of this report can be accessed at http://www.watchlistnews.com/neurocrine-biosciences-inc-forecasted-to-earn-fy2020-earnings-of-1-92-per-share-nbix/1120805.html.

Neurocrine Biosciences (NASDAQ:NBIX) traded up 1.65% during mid-day trading on Thursday, hitting $43.15. The stock had a trading volume of 926,588 shares. The firm’s 50-day moving average is $41.58 and its 200 day moving average is $46.19. The stock’s market cap is $3.75 billion. Neurocrine Biosciences has a one year low of $32.18 and a one year high of $55.15.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Tuesday, February 14th. The company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.05. During the same period last year, the company earned ($0.34) EPS.

A number of institutional investors have recently bought and sold shares of NBIX. Perceptive Advisors LLC bought a new stake in shares of Neurocrine Biosciences during the fourth quarter worth about $128,349,000. Orbimed Advisors LLC raised its stake in shares of Neurocrine Biosciences by 17.3% in the fourth quarter. Orbimed Advisors LLC now owns 2,128,774 shares of the company’s stock worth $82,384,000 after buying an additional 313,300 shares during the period. Alyeska Investment Group L.P. raised its stake in shares of Neurocrine Biosciences by 46.3% in the fourth quarter. Alyeska Investment Group L.P. now owns 645,536 shares of the company’s stock worth $24,982,000 after buying an additional 204,301 shares during the period. Two Sigma Investments LP raised its stake in shares of Neurocrine Biosciences by 1,898.2% in the fourth quarter. Two Sigma Investments LP now owns 83,923 shares of the company’s stock worth $3,248,000 after buying an additional 79,723 shares during the period. Finally, Janus Capital Management LLC raised its stake in shares of Neurocrine Biosciences by 10.6% in the fourth quarter. Janus Capital Management LLC now owns 2,356,485 shares of the company’s stock worth $91,203,000 after buying an additional 224,906 shares during the period. 97.60% of the stock is owned by hedge funds and other institutional investors.

This report was reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was illegally copied and republished in violation of US and international trademark and copyright law. The original version of this report can be accessed at http://www.watchlistnews.com/neurocrine-biosciences-inc-forecasted-to-earn-fy2020-earnings-of-1-92-per-share-nbix/1120805.html.

In related news, CEO Kevin Charles Gorman sold 3,750 shares of the firm’s stock in a transaction that occurred on Tuesday, January 10th. The shares were sold at an average price of $43.28, for a total value of $162,300.00. Following the completion of the transaction, the chief executive officer now owns 240,927 shares of the company’s stock, valued at approximately $10,427,320.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Christopher Flint Obrien sold 1,750 shares of the firm’s stock in a transaction that occurred on Tuesday, January 10th. The stock was sold at an average price of $43.35, for a total transaction of $75,862.50. Following the completion of the transaction, the insider now directly owns 31,794 shares of the company’s stock, valued at approximately $1,378,269.90. The disclosure for this sale can be found here. Insiders sold a total of 32,816 shares of company stock valued at $1,387,036 in the last ninety days. Company insiders own 4.80% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders.

5 Day Chart for NASDAQ:NBIX

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.